Nyxoah Sa ( (NYXH) ) has released its Q3 earnings. Here is a breakdown of the information Nyxoah Sa presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Nyxoah SA is a medical technology company specializing in innovative treatments for Obstructive Sleep Apnea (OSA) through neuromodulation, with its lead product being the Genio system, a unique, leadless, and battery-free hypoglossal neurostimulation therapy.
In its third-quarter 2025 earnings report, Nyxoah highlighted a successful U.S. launch of its Genio system, marking the company’s first commercial implants and revenue generation in the U.S. market. The company achieved significant reimbursement coverage, securing approvals from major payers like Medicare and private insurers.
Nyxoah reported a 56% year-over-year revenue growth, reaching €2.0 million for the quarter. Despite this growth, the company faced an operating loss of €24.4 million, attributed to increased expenses in research and development and selling, general, and administrative areas, primarily due to the U.S. market expansion efforts. The company’s cash position decreased to €22.5 million by the end of September 2025.
The company’s strategic focus on training surgeons and establishing strong referral networks has shown early success, with 111 surgeons trained and multiple accounts already implementing the Genio system. Reimbursement progress continues with updates from major payers, enhancing patient access to the Genio system.
Looking ahead, Nyxoah’s management remains optimistic about sustaining growth in the U.S. market, supported by the recent financing transaction and the positive reception of the Genio system among healthcare providers.